NCT03339453View on ClinicalTrials.gov

A Study of Nasal Glucagon in Participants With Type 1 Diabetes Mellitus

PHASE1CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

November 10, 2017

Primary Completion Date

December 17, 2017

Study Completion Date

January 13, 2018

Conditions
HypoglycemiaDiabetes Mellitus, Type 1
Interventions
DRUG

Nasal Glucagon

Administered nasally

DRUG

Intramuscular Glucagon

Administered IM

Trial Locations (2)

55116

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Mainz

Unknown

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Neuss

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT03339453 - A Study of Nasal Glucagon in Participants With Type 1 Diabetes Mellitus | Biotech Hunter | Biotech Hunter